Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof

Light single-chain fusion polypeptides, encoding nucleic acid molecules and host cells

Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins

RECEPTOR

NANOSTRUCTURED PROTEINS AND USES THEREOF

Chimeric antigen receptor and methods of use thereof

Immunogenic proteins against

Chimeric antigen receptors (CARs), compositions and methods thereof

Compositions and methods for antigen targeting to CD180

IgG binding peptides and multifunctional antigen-binding proteins comprising the same

Gene transfer systems for stem cell engineering

WNT SIGNALING AGONIST MOLECULES

WNT SIGNALING AGONIST MOLECULES

Mutant tumor necrosis factor receptor superfamily (TNFsfR) ligands and methods of making and using same

Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers

METHODS AND COMPOSITIONS OF A FOLLICLE STIMULATING HORMONE RECEPTOR IMMUNORECEPTOR OR CHIMERIC ANTIGEN RECEPTOR

Twin immune cell engager

Polypeptides

Transduced T cells expressing human SSTR2 and application thereof

REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES

Modified virus-like particles of CMV

Chimeric antigen receptor (CAR) comprising a CD19-binding domain

Interleukin 15 (IL-15) variants

Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins

Antibody/T-cell receptor chimeric constructs and uses thereof

Methods of making T cell compositions

COLLAGEN-LOCALIZED IMMUNOMODULATORY MOLECULES AND METHODS THEREOF

Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers

Antigen-specific tolerance and compositions for induction of same

Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy

Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins

Antigen-binding fusion proteins with modified HSP70 domains

Multi-level specific targeting of cancer cells

CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY

METHODS FOR USE OF PROINSULIN TRANSFERRIN FUSION PROTEINS AS PRODRUGS

CD20 scFv-ELPs methods and therapeutics

Chimeric antigen receptors and methods of use

Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy

Compositions comprising PCSK9-binding molecules and methods of use

Chimeric chlorotoxin receptors

ALK7 ANTAGONISTS AND USES THEREOF

PSMA-specific binding proteins

Multivalent regulatory T cell modulators

Chimeric antigen receptors (CARs), compositions and methods thereof

PLASMA CELL CYTOKINE VEHICLE CONTAINING FUSION PROTEINS FOR TARGETED INTRODUCTION OF SIRNA INTO CELLS AND TISSUES

I domain chimeric antigen receptor specific to ICAM-1

Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers

Protein and protein conjugate for diabetes treatment, and applications thereof

BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy

Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers

Erythrocyte-binding therapeutics

Multifunctional heteromultimeric constructs

Zika as a cell penetrating peptide for delivery to the brain

Methods for transduction and cell processing

EFFECTIVE GENERATION OF TUMOR-TARGETED T CELLS DERIVED FROM PLURIPOTENT STEM CELLS

Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers

Methods and therapeutics comprising ligand-targeted ELPs

Bispecific signaling agents and uses thereof

Targeted modified TNF family members

Methods using GDF-15 antibodies for treatment of pulmonary arterial hypertension

Clec9A binding agents

Chimeric proteins and methods of immunotherapy

Phage conjugates and uses thereof

Anti-PD-L1 and IL-2 cytokines

Peptides and combinations of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers

Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers

Herpesvirus with modified glycoprotein B

COMPOSITIONS AND METHODS TO MODIFY CELLS FOR THERAPEUTIC OBJECTIVES

NOVEL IMMUNOCONJUGATES

CAR expression vector and CAR-expressing T cells

Immunoconjugates

P97 fusion proteins

Vaccines against HPV and HPV-related diseases

Fusion proteins comprising a non-cytotoxic protease, a translocation domain, and a targeting moiety that binds a galanin receptor and methods for treating, preventing or ameliorating pain using such fusion proteins

Polypeptides for inhibiting complement activation

Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers

IL2 and TNF immunoconjugates

Neonatal Fc Receptor Binding Dimer and Methods of Use

Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers

Compositions and methods for TCR reprogramming using fusion proteins

Delivery of therapeutic agents by a collagen binding protein

Conjugates for targeted cell surface editing

Bi-specific molecule for cell-specific Notch inhibition and related methods and compositions

Programmable protein circuits in living cells

POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION

Antibody/T-cell receptor chimeric constructs and uses thereof

MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF

Targeted Therapeutic Proteins

Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells

Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells

Chimeric antigen receptors targeting CD-19

Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR

GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE

Binding molecules with modified J-chain

Antigen Binding Molecules comprising a TNF family ligand trimer and PD1 binding moiety

CD40L single-chain fusion polypeptides and encoding nucleic acids

Fusion protein comprising apelin and an anti-APLNR antibody

CTLA4-binding protein peptide-linker masks

HCMV entry inhibitors

Chimeric antigen receptor (CAR) comprising a CD19-binding domain

COMPOSITIONS AND METHODS RELATED TO THERAPEUTIC CELL SYSTEMS FOR TUMOR GROWTH INHIBITION

Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers

Multi-level specific targeting of cancer cells

Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins

Nipah virus envelope glycoprotein pseudotyped lentivirus

Compositions and methods for antigen targeting to CD180

Receptor targeting constructs and uses thereof

SUPPRESSION OF CANCER

CTLA4-IG immunoadhesins

Truncated Constructs Related To RIPK3

Polynucleotides encoding bispecific chimeric antigen receptors

COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES

Compositions and methods for tumor transduction

Chimeric proteins and their use in identifying anti-deubiquitinase compounds

Fusion proteins of PD-1 and 4-1BB

Desmoglein 2 (DSG2) binding proteins and uses therefor

M971 chimeric antigen receptors

Polypeptides and uses thereof for reducing CD95-mediated cell motility

Bacteriophage-polymer hybrid

IMMUNE-CHECKPOINT INHIBITORS FOR USE IN THE TREATMENT OF BLOOD-BORNE CANCERS

Oncolytic adenovirus encoding a B7 protein or active fragment

CD8 binding agents

L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability

Therapeutic fusion proteins

Engineered antigen presenting cells and uses thereof

Cell

METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF

CD27 ligand (CD27L) single-chain fusion polypeptides

Antibody/T-cell receptor chimeric constructs and uses thereof

Synthetic protein for modulating gene expression

Fusokines involving cytokines with strongly reduced receptor binding affinities

METHODS AND COMPOSITIONS FOR BINDING VEGF

SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF

Chimeric antigen receptor (CAR) comprising a CD22-binding domain

NKG2D decoys

HIGH AFFINITY NY-ESO T CELL RECEPTORS

Heterodimer molecule based on CH3 domain, and preparation method and use thereof

Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains

IMMUNOMODULATORY PROTEINS

Immunogenic construct comprising an EBV-cell antigen and a targeting moiety and applications thereof

METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY

SIRP alpha-antibody fusion proteins

Binding-triggered transcriptional switches and methods of use thereof

Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same

Synthetic notch protein for modulating gene expression

Chimeric proteins and methods of immunotherapy

Immunogenic proteins against clostridium difficile

TARGETING OF CYTOKINE ANTAGONISTS

Targeting of human interferon antagonists

Targeted and mutated human-interferon fusion proteins

Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers

Bispecific antibodies specifically binding to PD1 and LAG3

Immunoconjugates

Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins

Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins

Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins

Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins

PSMA-specific binding proteins

Chimeric receptor with ligand binding exodomain and cytokine and T cell signalling endodomains

Oligomers for TNF superfamily inhibition, methods of making and using

IL-15 and IL-15Rα sushi domain based immunocytokines

Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

Chimeric antigen receptors and methods of use

Method for treating a muscle-related disorder with follistatin-related fusion proteins

Compositions and methods for treating diseases by inhibiting exosome release

Interferon analogs

Targeted modified TNF family members

Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues

Deimmunized therapeutic compositions and methods

Immune cell compositions and methods of use

Costimulatory chimeric antigen receptor T cells targeting IL13Rα2

Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins

Fibronectin type III domain-based fusion proteins

MULTIMERIZATION TECHNOLOGIES

Single-chain TL1A receptor agonist proteins

Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist proteins

Single-chain CD27-receptor agonist proteins

Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof

EPHA3 and multi-valent targeting of tumors

Single-chain CD137-receptor agonist proteins

LYMPHOTOXIN-BETA RECEPTOR-BINDING AGENTS, TARGETING ANTIBODIES, AND USES THEREOF

Fusion proteins and combination vaccines comprising haemophilus influenzae Protein E and Pilin A

Method of determining, identifying or isolating cell-penetrating peptides

METHOD FOR IN SITU INHIBITION OF REGULATORY T CELLS

Binding-triggered transcriptional switches and methods of use thereof

PHARMACEUTICAL COMPOSITION THAT IS ANTICANCER AND SUPPRESSES CANCER METASTASIS, CONTAINING, AS ACTIVE INGREDIENT, FUSION PEPTIDE SIMULTANEOUSLY TARGETING CANCER CELL AND TUMOR ASSOCIATED MACROPHAGE

Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity

Modified vaccinia virus strains for use in diagnostic and therapeutic methods

Novel Promiscuous HPV16-Derived T Helper Epitopes for Immunotherapy

Nucleic acids encoding artificial signal peptides and methods of production thereof

Antigen-specific tolerance and compositions for induction of same

Compositions for generation of immune tolerance to specific antigens

Compositions for inducing antigen-specific tolerance

METHODS AND COMPOSITIONS FOR TREATING HIV

Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody

Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies

Redirected cells with MHC chimeric receptors and methods of use in immunotherapy

Targeted modified TNF family members

CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF

Multivalent regulatory T cell modulators

Fusokines involving cytokines with strongly reduced receptor binding affinities

Fusion proteins that facilitate cancer cell destruction

Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies

T cell receptor-like antibodies specific for a PRAME peptide

ANTI-ROR1 CHIMERIC ANTIGEN RECEPTORS

Smart car devices, DE car polypeptides, side CARs and uses thereof

Recombinant bi-functional fusion protein and preparation and application therefor

Oncolytic adenovirus encoding a B7 protein

Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands, and non-natural NKG2D ligands that bind non-natural NKG2D receptors

Method for treating eye diseases with a fusion protein of a tissue-penetrating peptide and anti-vascular endothelial growth factor

Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

ANTI-FCRN ANTIBODIES

Modified binding proteins inhibiting the VEGF-A receptor interaction

Polypeptides

Polypeptides

HYBRID CHIMERA POLYPEPTIDES AS DUAL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND PLATELET-DERIVED GROWTH FACTOR RECEPTOR

Targeting GIV-GEF-GI signaling for treating diverse diseases

OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF

Erythrocyte-binding therapeutics

Antigen binding molecules specific for an anti-CD19 scFv

Protein-based T-cell receptor knockdown

Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R

IMMUNOMODULATORY PROTEINS

Antibody/T-cell receptor chimeric constructs and uses thereof

Chimeric antigen receptor and methods of use thereof

Engineered botulinum neurotoxin

HER2/ErbB2 Chimeric Antigen Receptor

Binding-triggered transcriptional switches and methods of use thereof

IL2 and TNF immunoconjugates

Hepatitis B therapeutic vaccines

Recombinant TNF ligand family member polypeptides with antibody binding domain and uses thereof

HIGH AFFINITY NY-ESO T CELL RECEPTORS

Transduced T cells expressing human SSTR2 and application thereof

Single-chain CD40-receptor agonist proteins

I domain chimeric antigen receptor specific to ICAM-1

TARGETING TRASTUZUMAB-RESISTANT HER2+ BREAST CANCER WITH A HER3-TARGETING NANOPARTICLE

Methods and compositions of a follicle stimulating hormone receptor immunoreceptor

Targeting of human interferon antagonists

Targeted therapeutic proteins

Chimeric antigen receptor (CAR) comprising a CD19-binding domain

Polymeric Fc proteins and methods of screening to alter their functional characteristics

ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE

IMMUNOMODULATORY FUSION PROTEINS AND USES THEREOF

Inhibitory chimeric antigen receptors

Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15Ra and therapeutic uses thereof

Oncolytic adenovirus encoding a B7 protein

Chimeric antigen receptor and methods of use thereof

Compositions and methods for expressing polypeptides on the surface of cells

Compositions and methods to modify cells for therapeutic objectives

Chimeric antigen receptors specific for carbonic acid anhydrase IX

Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof

SIRP alpha-antibody fusion proteins

Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide, methods and uses therefor

CHIMERIC ANTIGEN RECEPTOR COMBINATION THERAPY FOR TREATING TUMORS

METHOD OF TREATING TUMORS WITH NK AND NKT CELLS EXPRESSING ANTI-SSEA4 CHIMERIC ANTIGEN RECEPTORS

ANTI-SSEA4 CHIMERIC ANTIGEN RECEPTORS AND THEIR USE FOR TREATING CANCER

Targeted human-interferon fusion proteins

Compositions and methods for tumor transduction

Affinity chromatography wash buffer

Engineered T cells and uses therefor

Methods for engineering allogeneic and immunosuppressive resistant T cell immunotherapy

CEACAM6 CAR immune cells to treat cancers

ANTI-TAU CONSTRUCTS

Methods for treating inflammation with fusion proteins comprising interleukin-2 and interleukin-33

CHIMERIC ANTIGEN RECEPTOR TARGETING OF TUMOR ENDOTHELIUM

Chimeric antigen receptors, compositions, and methods

Nucleic acids encoding a fusion protein useful for multi-level specific targeting of cancer cells

AN IMMUNOTOXIN FOR USE IN THE TREATMENT OF LEISHMANIASIS

METHODS OF TREATING IgA NEPHROPATHY AND HENOCH-SCHONLEIN PURPURA NEPHRITIS USING A B-CELL ACTIVATING FACTOR (BAFF) INHIBITOR

T cell which co-expresses a CD19 chimeric antigen receptor and a CD22 chimeric antigen receptor

Method of treating cancer with a multiple integrin binding Fc fusion protein

Antibodies and immunocytokines

Cysteine engineered fibronectin type III domain binding molecules

Soluble universal ADCC-enhancing synthetic fusion gene and peptide technology and its use thereof

Compositions and methods for T cell delivery of therapeutic molecules

Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells

Anti-GPIIB/IIIA antibodies and uses thereof

Compositions and methods for improved car-T cell therapies

WNT SIGNALING AGONIST MOLECULES

Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers

Cell

Tetrafunctional bacteriophage

Chimeric antigen receptor and methods of use thereof

Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

TETRAVALENT TLR9 BISPECIFIC ANTIBODY

BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES

Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

FUSION PROTEINS AND METHODS FOR TREATING, PREVENTING OR AMELIORATING PAIN

Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand

Designer collagens and use thereof

CARTILAGE-BINDING FUSION PROTEINS

Isolated nucleic acid encoding an anti-IGF-1R antibody

Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies

BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES

Cytokine-based fusion proteins for treatment of immune disorders

Glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL) single-chain fusion polypeptides

Modified virus-like particles of CMV

CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF